Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNEQ Sorrento Therapeutics Inc
SPI SPI Energy Co Ltd
AMC AMC Entertainment Holdings Inc
BOF BranchOut Food Inc
KITT Nauticus Robotics Inc
EAT Brinker International Inc
JCSE JE Cleantech Holdings Ltd
GVP GSE Systems Inc
CURV Torrid Holdings Inc
APRN Blue Apron Holdings Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Closing Price
Day's Change
-0.0062 (-6.19%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

Synopsys (SNPS) Adds New Extension to Its EDA

10:59 am ET September 8, 2023 (Zacks) Print

Synopsys SNPS recently unveiled Synopsys.da, an extension to its existing Electronic Design Automation (“EDA”) Solution called This new upgrade will allow chipmakers to obtain actionable design insights to uncover power, performance and area (PPA) opportunities in all stages of the integrated circuit (IC) chip development process.

Synopsys' EDA Solution has been used for chip-design optimization. The company has been focusing on enhancing its capabilities by introducing AI-driven tests and verification flows.

With the addition of this new extension, the EDA is expected to gain the capability to analyze extensive streams of data related to fab equipment process control. This analysis will result in enhanced operational efficiencies as well as the optimization of product quality and fab yield.

Synopsys Benefits From a Strong Partner Base

Synopsys benefits from an expanding partner base that includes the likes of Intel INTC, Advanced Micro Devices AMD, Juniper Networks, Realtek, Teradici, NetLogic Microsystems, Toshiba and Wolfson.

Intel entered a strategic partnership with Synopsis in August 2023. The collaboration between these two leading chip makers was aimed at leveraging Intel’s extensive network of chip foundry factories while using Synopsys’ IP and EDA technology. This partnership is part of Intel's efforts to regain its position as the leading chip manufacturer by 2025.

Synopsys, Inc. Price and Consensus

Synopsys, Inc. Price and Consensus

Synopsys, Inc. price-consensus-chart | Synopsys, Inc. Quote


In March 2023, Advanced Micro Devices and Synopsys collaborated to enable their mutual customers to use the latest generation of AMD EPYC processors. Synopsys offered a comprehensive portfolio of EDA solutions tailored specifically for use with AMD EPYC processors.

Zacks Rank & Another Stock to Consider

Synopsis currently has a Zacks Rank #2 (Buy).

Synopsys shares have rallied 43.5% year to date, outperforming the Zacks Computer and Technology sector’s return of 39.7%.

NVIDIA NVDA is a top-ranked stock in the broader sector, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

NVIDIA’s long-term earnings growth is pegged at 13.5%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intel Corporation (INTC): Free Stock Analysis Report
Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report
NVIDIA Corporation (NVDA): Free Stock Analysis Report
Synopsys, Inc. (SNPS): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.